SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Peto J,Decarli A,La Vecchia C,La Vecchia C,Levi F,Negri E. The European mesothelioma epidemic. Br J Cancer. 1999; 79: 666672.
  • 2
    Vogelzang NJ,Rusthoven JJ,Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21: 26362644.
  • 3
    Scagliotti GV,Shin DM,Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003; 21: 15561561.
  • 4
    Ceresoli GL,Zucali PA,Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006; 24: 14431448.
  • 5
    Giaccone G,O'Brien ME,Byrne MJ,Bard M,Kaukel E,Smit B. Phase II trial of ZD0473 as second-line therapy in mesothelioma. Eur J Cancer. 2002; 38: S19S24.
  • 6
    Porta C,Zimatore M,Bonomi L, et al. Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer. 2005; 48: 429434.
  • 7
    Fizazi K,Doubre H,Le Chevalier T, et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol. 2003; 21: 349354.
  • 8
    Fennell DA,Steele JP,Shamash J, et al. Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma. Cancer. 2007; 109: 9399.
  • 9
    Vogelzang NJ. Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma? J Clin Oncol. 1999; 17: 26262627.
  • 10
    Sorensen JB,Sundstrom S,Perrell K,Thielsen AK. Pemetrexed as second-line treatment in malignant pleural mesothelioma (MPM) after platinum-based first-line treatment. J Thorac Oncol. 2007; 2: 147152.
  • 11
    Jassem J,Ramlau R,Santoro A, et al. A randomized phase III trial comparing pemetrexed plus best supportive care (BSC) vs BSC in previously treated patients (pts) with advanced pleural mesothelioma (MPM) [abstract]. Ann Oncol. 2006; 17: 214a.
  • 12
    Rusch VW. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care? J Clin Oncol. 2003; 21: 26292630.
  • 13
    Kindler HL,Van Meerbeeck JP. The role of gemcitabine in the treatment of malignant mesothelioma. Semin Oncol. 2002; 29: 7076.
  • 14
    Van Meerbeeck JP,Baas P,Debruyne C, et al. A phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer. 1999; 85: 25772582.
  • 15
    Steele JP,Shamash J,Evans MT,Gower NH,Tischkowitz MD,Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000; 18: 39123917.
  • 16
    Byrne MJ,Davidson JA,Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999; 17: 2530.
  • 17
    Nowak A,Byrne M,Williamson R. Multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002; 87: 491496.
  • 18
    Van Haarst JM,Baas P,Manegold C, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002; 86: 342345.
  • 19
    Favaretto AG,Aversa SML,Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma. A multicentric phase II study. Cancer. 2003; 97: 27912797.
  • 20
    Bischoff HG,Manegold C,Knopp M,Blatter J,Drings P. Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. Proc Am Soc Clin Oncol. 1998; 17: 464a. Abstract 1784.
  • 21
    Manegold C,Symanowski J,Gatzemeier U, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005; 16: 923927.
  • 22
    Mbidde EK,Harland SJ,Calvert AH,Smith IE. Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother Pharmacol. 1986; 18: 284285.
  • 23
    Raghavan D,Gianoutsos P,Bishop J, et al. Phase II trial of carboplatin in the management of malignant mesothelioma. Clin Oncol. 1990; 8: 151154.
  • 24
    Vogelzang NJ,Goutsou M,Corson JM, et al. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol. 1990; 27: 239242.
  • 25
    Schutte W,Blankenburg T,Lauerwald K, et al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clin Lung Cancer. 2003; 4: 294297.
  • 26
    Serke M,Xanthopoulos A,Bauer T. Second line chemotherapy in malignant pleural mesothelioma with oxaliplatin/gemcitabine [abstract]. Ann Oncol. 2006; 17( suppl 9): 231a.
  • 27
    Delord JP,Raymond E,Chaouche M, et al. A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies. Ann Oncol. 2000; 11: 7379.
  • 28
    Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Chest. 1995; 108: 11221128.
  • 29
    National Cancer Institute. Common Toxicity Criteria manual, version 3.0: July 16, 2003. Available from: http://ctep.cancer.gov/reporting/ctc.html. Accessed July 2006.
  • 30
    Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 110.
  • 31
    Kaplan EL,Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 32
    Schemper M,Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996; 17: 343346.
  • 33
    Curran D,Sahmoud T,Therasse P,van Meerbeeck J,Postmus PE,Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998; 16: 145152.
  • 34
    Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly censored data. Biometrika. 1965; 52: 203223.
  • 35
    Muers M,Fisher P,Snee M, et al. A randomized phase III trial of active symptom control (ASC) with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma: first results of the Medical Research Council (MRC)/British Thoracic Society (BTS) MS01 trial. J Clin Oncol, 1997 ASCO Annual Meeting Proceedings, Part 1. 2007; 25: 18S( June 20 suppl). Abstract LBA7525.
  • 36
    Korn EL,Arbuck SG,Pluda JM,Simon R,Kaplan RS,Christian MC. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol. 2001; 19: 265272.
  • 37
    Van Glabbeke M,Verweij J,Judson I,Nielsen OS;EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002; 38: 543549.
  • 38
    Fennell D,Steele J,Sheaff M, et al. Response of malignant pleural mesothelioma to chemotherapy does not confer a survival advantage. Lung Cancer. 2005; 49: S220. Abstract P-397.
  • 39
    Francart J,Legrand C,Sylvester R, et al. Progression-free survival rate as primary endpoint for phase II cancer clinical trials: application to mesothelioma. The EORTC Lung Cancer Group. J Clin Oncol. 2006; 24: 30073012.
  • 40
    Zucali PA,Giaccone G. Biology and management of malignant pleural mesothelioma. Eur J Cancer. 2006; 42: 27062714.